Figure 1
From: Upregulation of CYP2S1 by oxaliplatin is associated with p53 status in colorectal cancer cell lines
Inhibition of colorectal cancer cell growth by oxaliplatin.
(A) Growth inhibition of 3 colorectal cancer cell lines, as detected by the CCK8 assay. HCT116(wild-type p53), HT29, and SW480 cells were treated with different concentrations of oxaliplatin for 24 h; a CCK8 assay was used to detect inhibition of cell growth as described in Materials and Methods. The rate of growth inhibition was higher in HCT116 cells than in HT29 or SW480 cells (p < 0.05). Data are expressed as the means ± SD of three independent experiments. (B) Isogenic p53+/+ HCT116 (wild-type p53) and HCT116 cells in which p53 was stably knocked down (p53−/− cells) were treated with 20 μM oxaliplatin for 24–72 h. A CCK8 assay was used to detect cell growth inhibition (*p < 0.05). Data are expressed as the means ± SD of three independent experiments. (C) Cells were treated as described in A and B, and p53 was detected in cell lysates by western blotting. The results shown are representative of three experiments. (D) p53+/+HCT116 cells and p53−/− HCT116 cells were treated with or without oxaliplatin (20 μM) for 24 h; total protein was extracted, and the protein levels of total TAp63 and TAp73 were analyzed by western blotting. The results shown are representative of three experiments.
